Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

類似資料

• Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
  著者:: Dimopoulos, M A, 等
  出版事項: (2017)
• Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
  著者:: Dimopoulos, Meletios A., 等
  出版事項: (2017)
• Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
  著者:: Ludwig, Heinz, 等
  出版事項: (2019)
• Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
  著者:: Avet-Loiseau, Hervé, 等
  出版事項: (2016)
• Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
  著者:: Dimopoulos, Meletios, 等
  出版事項: (2018)